Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:50 PM
Ignite Modification Date:
2025-12-24 @ 4:50 PM
NCT ID:
NCT07135050
Brief Summary:
The goal of this clinical trial is to learn if MZ-1866 is a safe and tolerable treatment for children and adults with Pitt Hopkins Syndrome.
To evaluate the safety of MZ-1866, the following will be evaluated:
* frequency and severity of adverse events
* physical exam, laboratory results and electrocardiogram findings
Participants will:
* receive a single dose of MZ-1866 by intracerebroventricular injection
* be seen by the study physician and site staff periodically to assess changes to their health status
* be periodically evaluated using neurodevelopmental tools
Caregivers will:
* be interviewed periodically about the health status and development of the participant
* keep diaries and complete periodic questionnaires regarding participant symptoms
Study:
NCT07135050
Study Brief:
Protocol Section:
NCT07135050